Register for email alerts and news feeds:
This journal | BMJ Group
rss
Annals of the Rheumatic Diseases 1998;57:249-251; doi:10.1136/ard.57.4.249
Copyright © 1998 BMJ Publishing Group Ltd & European League Against Rheumatism.
Ann Rheum Dis 1998;57:249-251 ( April )

Concise reports

Decreased serum apolipoprotein AII/AI ratio in systemic amyloidosis Toshiyuki Yamada,a Tetsuo Ozawa,b Fumitake Gejyo,c Yasuaki Okuda,d Kiyoshi Takasugi,d Osamu Hotta,e Yoshihisa Itoha

a Department of Clinical Pathology, Jichi Medical School, Tochigi, Japan, b Department of Clinical Laboratory Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan, c Department of Laboratory and Clinical Medicine, Fukui Medical School, Fukui , Japan, d Centre for Rheumatic Diseases, Dohgo Spa Hospital, Matsuyama, Japan, e Department of Nephrology, Sendai Shakaihoken Hospital, Sendai, Japan

Correspondence to: Dr T Yamada, Department of Clinical Pathology, Yakushiji, Minamikawachi, Tochigi 329-04, Japan.

Accepted for publication 27 February 1998

OBJECTIVE---To investigate if serum apolipoprotein A-I and A-II (apoAI and apoAII) concentrations change in subjects with systemic amyloidosis secondary to underlying disorders.
METHODS---Serum concentrations of apoAI and apoAII were measured in 21 multiple myeloma patients, including eight with amyloidosis; 95 rheumatoid arthritis patients, including 45 with amyloidosis; and 73 haemodialysis patients, including 32 with amyloidosis.
RESULTS---ApoAII values tended to be reduced in subjects with amyloidosis in each group, but could not effectively distinguish amyloidosis. However, apoAII/AI ratios were significantly lower in subjects with amyloidosis in all groups. The ratio of 0.2 had diagnostic sensitivity and specificity for amyloidosis; 50% and 100%, respectively, in multiple myeloma; 80% and 78%, respectively, in rheumatoid arthritis; and 46% and 90%, respectively, in patients requiring long term haemodialysis.
CONCLUSION---The apoAII/AI ratio can be a useful biochemical marker of suspect amyloidosis in patients with underlying diseases, especially those with rheumatoid arthritis.

Keywords: amyloidosis; apolipoprotein; rheumatoid arthritis; haemodialysis


© 1998 by Annals of the Rheumatic Diseases

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest Rheumatology Jobs

Rheumatology Jobs